Selpercatinib in Chinese patients with -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial

Selpercatinib in Chinese patients with -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial

Background: Selpercatinib is approved for the treatment of RET -fusion-positive non-small-cell lung cancer (NSCLC). Objective: We present a final update on LIBRETTO-321 to enhance the understanding of long-term efficacy and safety in Chinese patients. Design: This open-label, multicenter, phase II s...

Full description

Bibliographic Details
Main Authors: Shun Lu, Ying Cheng, Dingzhi Huang, Yuping Sun, Lin Wu, Chengzhi Zhou, Jianying Zhou, Ye Guo, Jingxin Shao, Wanli Zhang
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241307199

Internet

https://doi.org/10.1177/17588359241307199

Similar Items